CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Inclusion Criteria: * Subject must meet all the following criteria to be selected: 1. Willing to provide consent/assent for participation in the study by patient or his/her legal guardian; 2. Male or Female subjects age ≥18 and ≤55 years; 3. Evidence of relapsed/refractory CD19+ B cell hematological malignancies. The most common relapsed/refractory B cell hematological malignancies include: (1) B cell acute lymphoblastic leukemia (B-ALL); (2) B cell lymphomas, including indolent B cell lymphoma (CLL, FL, MZL, LPL, HCL) and aggressive B cell lymphoma (DLBCL, BL, MCL)； 4. Subjects (20 subjects of B cell acute lymphoblastic leukemia and 20 subjects of B cell lymphoma) with the following conditions: 1. Failure to achieve complete remission (CR) after at least two lines of standard chemotherapy while not suitable for HSCT (auto/allo-HSCT)； 2. Relapse after CR, but not eligible for HSCT (auto/allo-HSCT); 3. Failure to achieve remission or relapse after HSCT; 5. Leukemia patient confirmed by bone marrow aspiration that has not been alleviated; lymphoma patient with measurable or assessable lesions; 6. Adequate organ function: 1. Liver: ALT/AST ≥ 3 × ULN, total bilirubin ≤34.2 mol/L; 2. Kidney: Creatinine\<220 µmol/L, creatinine clearance rate (CCR) ≥ 60 mL/min; 3. Lung: arterial oxygen saturation ≥95%; 4. Heart: Left ventricular ejection fraction (LVEF) ≥40%; 5. Absolute lymphocyte count (ALC) ≥ 100/μL, absolute neutrophil count (ANC) ≥ 1,000/μL, platelets (PLT) ≥ 75,000/μL; 7. No prior anti-cancer therapy, including chemotherapy, radiotherapy, immunotherapy (immunosuppression) within 4 weeks prior to enrollment, and toxic reactions of all prior treatments recovered to grade ≤1 at the time of enrollment (except for low toxicity such as alopecia); 8. Presence of smooth peripheral superficial venous blood flow to fulfill intravenous infusion; 9. Karnofsky performance score ≥60; ECOG ≤2; estimated survival ≥3 months. Exclusion Criteria: * Subjects meeting one or more of the following criteria will be excluded: 1. Female patient who is pregnant or breastfeeding ; 2. Male or Female patient within Pregnancy Program in 1 year; 3. Unwilling or unable to guarantee effective contraceptive measures (condoms or contraceptives) within 1 year after enrollment; 4. Presence of uncontrolled infectious disease within 4 weeks prior to enrollment: 5. Active hepatitis B or hepatitis C infection; 6. HIV infection; 7. Active TB; 8. Presence of active malignancy other than disease under study, confirmed by pathology; 9. Severe autoimmune diseases or immunodeficiency; 10. Suffering from allergies; 11. Joining another clinical trial within 6 weeks prior to enrollment; 12. Using systemic corticosteroid within 4 weeks prior to enrollment (except for those who use inhaled steroids); 13. Psychiatric disorders; 14. History of epilepsy and seizures or other CNS pathology; 15. Addiction to or abuse of drugs; 16. Presence of any condition that, in the opinion of the investigator, would prohibit the patient from undergoing treatment under this protocol.